[.
]
Action/Kinetics:
Has both beta-1 and beta-2 receptor blocking activity. It has no membrane-stabilizing activity but does have moderate intrinsic sympathomimetic effects. Low lipid solubility.
t
1/2: 6 hr.
Duration, ophthalmic use: 12 hr. Approximately 50%-70% excreted unchanged in the urine.
Uses:
PO. Hypertension.
Investigational: Reduce frequency of anginal attacks.
Ophthalmic. Alone or with other drugs to lower IOP in chronic open-angle glaucoma and intraocular hypertension.
Contraindications:
Severe, persistent bradycardia. Bronchial asthma or bronchospasm, including severe COPD.
Special Concerns:
Dosage not established in children.
Additional Side Effects:
Ophthalmic use. Transient irritation, burning, tearing, conjunctival hyperemia, edema, blurred or cloudy vision, photophobia, decreased night vision, ptosis, blepharoconjunctivitis, abnormal corneal staining, corneal sensitivity.
How Supplied:
Ophthalmic solution: 1%;
Tablet: 2.5 mg, 5 mg
Dosage
?Tablets
Hypertension.
Initial: 2.5 mg once daily either alone or with a diuretic. If response is inadequate, the dose may be increased gradually to 5 mg and then 10 mg/day as a single dose.
Maintenance: 2.5-5 mg once daily. Doses greater than 10 mg/day are not likely to increase the beneficial effect and may decrease the response. Increase the dosage interval in clients with renal impairment.
Reduce frequency of anginal attacks.
10 mg/day.
?Ophthalmic Solution
Usual: 1 gtt in affected eye b.i.d. If the response is unsatisfactory, concomitant therapy may be initiated.
